ORLADEYO Treatment: Real-world Evidence on Reduced HAE Attack Rates for Patients with Normal C1-Inhibitor

Sunday, 2 June 2024, 05:12
The latest data presented by BioCryst highlights the significant reduction in attack rates among patients with Hereditary Angioedema (HAE) and normal C1-Inhibitor after initiating ORLADEYO treatment. This real-world evidence underscores the efficacy of ORLADEYO (berotralstat) in managing HAE symptoms and improving patient outcomes. The findings suggest a promising therapeutic approach for individuals with normal C1-Inhibitor facing HAE attacks, potentially revolutionizing treatment in this patient population.
https://store.livarava.com/b6790ad9-20b8-11ef-a3f8-9d5fa15a64d8.jpg
ORLADEYO Treatment: Real-world Evidence on Reduced HAE Attack Rates for Patients with Normal C1-Inhibitor

ORLADEYO Treatment for HAE Patients

The latest real-world evidence from BioCryst reveals a substantial reduction in attack rates among Hereditary Angioedema (HAE) patients with normal C1-Inhibitor after starting ORLADEYO treatment.

Potential Therapeutic Breakthrough

BioCryst's findings highlight the efficacy of ORLADEYO (berotralstat) in managing HAE symptoms and improving patient outcomes, offering a promising therapeutic option for those with normal C1-Inhibitor facing HAE attacks.

  • Significant reduction in attack rates observed
  • Improvement in patient outcomes demonstrated
Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe